Relationship of Injectable Antimicrobial Use and Resistance Rates in Pseudomonas aeruginosa by Using the Anatomical Therapeutic Chemical Classification/Defined Daily Dose System

Abstract

  Surveillance of injectable antimicrobial consumption was conducted at 55 institutes to elucidate the relationship between carbapenem consumption and imipenem or meropenem-resistant rates in Pseudomonas aeruginosa in the Tokai region using the Anatomical Therapeutic Chemical classification/Defined Daily Dose system. The consumption of antimicrobial agents (13.7 DDDs/100 bed days) in 2008 significantly increased compared to that (12.8 DDDs/100 bed days) in 2007 (p=0.010). In particular, cephalosporin consumption (from 5.3 DDDs/100 bed days to 5.6 DDDs/100 bed days, p=0.028) and glycopeptide consumption (from 0.4 DDDs/100 bed days to 0.5 DDDs/100 bed days, p=0.009) significantly increased. On the other hand, carbapenem consumption (1.3 DDDs/100 bed days) in 2008 was comparable to that (1.2 DDDs/100 bed days) in 2007 (p=0.418). These results are useful as an index for comparing intergroup and nationwide antimicrobial consumption. No relationship was found between the consumption of carbapenem and imipenem or meropenem-resistant rates in P. aeruginosa. Since the consumption of carbapenem seems to exert little influence on the resistance of P. aeruginosa, some factors other than carbapenem consumption should be considered.